Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
42.24
+1.24 (3.02%)
At close: Jan 22, 2026, 4:00 PM EST
42.44
+0.20 (0.47%)
Pre-market: Jan 23, 2026, 5:37 AM EST
Xenon Pharmaceuticals Employees
As of December 31, 2024, Xenon Pharmaceuticals had 327 total employees, including 316 full-time and 11 part-time employees. The number of employees increased by 68 or 26.25% compared to the previous year.
Employees
327
Change (1Y)
68
Growth (1Y)
26.25%
Revenue / Employee
$22,936
Profits / Employee
-$936,801
Market Cap
3.26B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 327 | 68 | 26.25% | 316 | 11 |
| Dec 31, 2023 | 259 | 46 | 21.60% | 251 | 8 |
| Dec 31, 2022 | 213 | 60 | 39.22% | 203 | 10 |
| Dec 31, 2021 | 153 | 24 | 18.60% | 149 | 4 |
| Dec 31, 2020 | 129 | 25 | 24.04% | 123 | 6 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Beam Therapeutics | 483 |
| Arcutis Biotherapeutics | 342 |
| Tarsus Pharmaceuticals | 323 |
| Alumis | 223 |
| Catalyst Pharmaceuticals | 181 |
| Liquidia | 170 |
| Viridian Therapeutics | 143 |
| IDEAYA Biosciences | 131 |
XENE News
- 2 days ago - Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study - GlobeNewsWire
- 6 days ago - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference - GlobeNewsWire
- 17 days ago - Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout - Seeking Alpha
- 6 weeks ago - Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript - Seeking Alpha
- 6 weeks ago - Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 - GlobeNewsWire